Finch Therapeutics Group, Inc. (FNCHQ)

Finch Therapeutics Group, Inc. engages in the development of microbiome drugs. Its platform includes Human-First Discovery that enables reverse translation from clinical data to engineer the composition of the microbiome based on disease-modifying mechanisms. The company was founded by Mark Smith, Andrew Noh, Tom Borody and Zain Kassam in 2014 and is headquartered in Boston, MA.

Sector: Biological Products, (No Diagnostic Substances)

Industry: Biotechnology